Abstract
Increasing evidence suggests that abnormalities in amino neurotransmission are associated with the neurobiology of depression. Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function. In humans, depressed patients have lower plasma, CSF and brain GABA concentrations than non-depressed comparison subjects. The recent discovery that several anticonvulsant and GABA-mimetic agents possess mood stabilizing and antidepressant properties has further increased interest in these findings. This review outlines the existing literature investigating the possible involvement of GABA in the neurobiology of depression and briefly highlights how this information may afford new targets for antidepressant drug development.
Keywords: Psychiatry, mood disorders, pathophysiology, GABA, neurosteroid
CNS & Neurological Disorders - Drug Targets
Title: GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action
Volume: 6 Issue: 2
Author(s): Gerard Sanacora and Aybala Saricicek
Affiliation:
Keywords: Psychiatry, mood disorders, pathophysiology, GABA, neurosteroid
Abstract: Increasing evidence suggests that abnormalities in amino neurotransmission are associated with the neurobiology of depression. Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function. In humans, depressed patients have lower plasma, CSF and brain GABA concentrations than non-depressed comparison subjects. The recent discovery that several anticonvulsant and GABA-mimetic agents possess mood stabilizing and antidepressant properties has further increased interest in these findings. This review outlines the existing literature investigating the possible involvement of GABA in the neurobiology of depression and briefly highlights how this information may afford new targets for antidepressant drug development.
Export Options
About this article
Cite this article as:
Sanacora Gerard and Saricicek Aybala, GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action, CNS & Neurological Disorders - Drug Targets 2007; 6 (2) . https://dx.doi.org/10.2174/187152707780363294
DOI https://dx.doi.org/10.2174/187152707780363294 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Local Anesthetis and Adjuvants in Pediatric Regional Anesthesia
Current Drug Targets Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Application of Computational Techniques to Unravel Structure-Function Relationship and their Role in Therapeutic Development
Current Topics in Medicinal Chemistry Dipeptidyl-Peptidase IV (DPP IV/CD26)-Activated Prodrugs: A Successful Strategy for Improving Water Solubility and Oral Bioavailability
Current Medicinal Chemistry The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Synthesis and Evaluation of Macromolecule-Bound Derivatives of a Peptidyl-1-ß-D-arabinofuranosylcytosine Prodrug
Drug Metabolism Letters Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Gene Expression Studies to Investigate Disease Mechanisms in Rheumatoid Arthritis: Does Angiogenesis Play a Role?
Current Rheumatology Reviews Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Current Topics in Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Chloride Channel Expression and Functional Diversity in the Immune Cells of Allergic Diseases
Current Molecular Medicine Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Low Molecular Weight Inhibitors of the Protease Anthrax Lethal Factor
Mini-Reviews in Medicinal Chemistry A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry